Napredna pretraga

Pregled bibliografske jedinice broj: 952804

Left ventricular ejection fractions in HER2- positive breast cancer patients undergoing trastuzumab treatment


Vučinić, Damir; Skočilić, Iva; Belac-Lovasić, Ingrid; Bukovica, Ana-Marija; Mavrinac, Martina; Lovasić, Franjo; Zamolo, Gordana
Left ventricular ejection fractions in HER2- positive breast cancer patients undergoing trastuzumab treatment // 17th Zagreb International Medical Summit for students and young doctors / Damir Martinović, Luka Lovrenčić (ur.).
Zagreb: Croatian Medical Association - Student Section, 2017. str. 14-15 (poster, domaća recenzija, sažetak, ostalo)


Naslov
Left ventricular ejection fractions in HER2- positive breast cancer patients undergoing trastuzumab treatment

Autori
Vučinić, Damir ; Skočilić, Iva ; Belac-Lovasić, Ingrid ; Bukovica, Ana-Marija ; Mavrinac, Martina ; Lovasić, Franjo ; Zamolo, Gordana

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Skup
17th Zagreb International Medical Summit for students and young doctors

Mjesto i datum
Zagreb, Hrvatska, 23-25.11.2017

Vrsta sudjelovanja
Poster

Vrsta recenzije
Domaća recenzija

Ključne riječi
Breast cancer ; Cardiotoxicity ; Human epidermal growth factor receptor 2 ; Trastuzumab ; Ventricular ejection fraction

Sažetak
Trastuzumab (TZB) is a recombinant humanized monoclonal antibody, used for the treatment of human epidermal growth factor receptor 2 (HER2) positive breast cancer. Cardiotoxicity is an important side effect of TZB therapy, which manifests mainly as a decrease in left ventricular ejection fraction (LVEF). The aim of this study was to assess the cardiac safety during TZB treatment and investigate the possible influence of other therapy options on trastuzumab-related cardiotoxicity.

Izvorni jezik
Engleski

Znanstvena područja
Farmacija, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)



POVEZANOST RADA


Ustanove
Medicinski fakultet, Rijeka,
Sveučilište u Rijeci

Časopis indeksira:


  • Scopus
  • MEDLINE